Literature DB >> 30471778

PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice.

Marina Kjaergaard1, Casper Bo Gravesen Salinas2, Jens F Rehfeld3, Anna Secher2, Kirsten Raun4, Birgitte S Wulff4.   

Abstract

Peptide YY(3-36) ((PYY(3-36)) and glucagon like peptide 1 (GLP-1) in combination reduce food intake and body weight in an additive or synergistic manner in animal models and in humans. Nevertheless, the mechanisms behind are not completely understood. The present study aims to investigate the effect of combining PYY(3-36) and the GLP-1 receptor agonist exendin-4 (Ex4) by examining acute food intake and global neuronal activation as measured by c-fos in C57BL/6 J mice. An additive reduction in food intake was found 1.5 h after s.c dosing with the combination of PYY(3-36) (200 μg/kg) and Ex4 (2.5 μg/kg). This was associated with a synergistic enhancement of c-fos reactivity in central amygdalar nucleus (CeA), rostral part of the mediobasal arcuate nucleus (ARH), supratrigeminal nucleus (SUT), lateral parabrachial nucleus (PB), area postrema (AP) and nucleus tractus solitarius (NTS) compared to vehicle, PYY(3-36) and Ex4 individually dosed mice. The regions activated by Ex4 individually and PYY(3-36) and Ex4 in combination resembled each other, but the combination group had a significantly stronger c-fos response. Twenty-five brain areas were activated by PYY(3-36) and Ex4 in combination compared to vehicle versus nine brain areas by Ex4 individually. No significant increase in c-fos reactivity was found by PYY(3-36) compared to vehicle dosed mice. The neuronal activation of ARH and the AP/NTS to PB to CeA pathway is important for appetite regulation while SUT has not previously been reported in the regulation of energy balance. As PYY(3-36) and Ex4 act on different neurons leading to recruitment of different signalling pathways within and to the brain, an interaction of these pathways may contribute to their additive/synergistic action. Thus, PYY(3-36) boosts the effect of Ex4 possibly by inducing less inhibition of neuronal activity leading to an enhanced neuronal activity induced by Ex4.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Appetite; Exendin-4; Global c-fos; PYY(3-36); Synergy

Mesh:

Substances:

Year:  2018        PMID: 30471778     DOI: 10.1016/j.npep.2018.11.004

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  10 in total

1.  Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP.

Authors:  Oleg G Chepurny; Minos-Timotheos Matsoukas; George Liapakis; Colin A Leech; Brandon T Milliken; Robert P Doyle; George G Holz
Journal:  J Biol Chem       Date:  2019-01-08       Impact factor: 5.157

Review 2.  A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors.

Authors:  Riley Merkel; Amanda Moreno; Yafang Zhang; Rachel Herman; Jennifer Ben Nathan; Sana Zeb; Suditi Rahematpura; Kamryn Stecyk; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt
Journal:  Neurosci Biobehav Rev       Date:  2021-10-29       Impact factor: 8.989

Review 3.  Leveraging the Gut to Treat Metabolic Disease.

Authors:  Ruth E Gimeno; Daniel A Briere; Randy J Seeley
Journal:  Cell Metab       Date:  2020-03-17       Impact factor: 27.287

Review 4.  Gut-brain communication and obesity: understanding functions of the vagus nerve.

Authors:  Hans-Rudolf Berthoud; Vance L Albaugh; Winfried L Neuhuber
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

5.  An Optimized Mouse Brain Atlas for Automated Mapping and Quantification of Neuronal Activity Using iDISCO+ and Light Sheet Fluorescence Microscopy.

Authors:  Johanna Perens; Casper Gravesen Salinas; Jacob Lercke Skytte; Urmas Roostalu; Anders Bjorholm Dahl; Tim B Dyrby; Franziska Wichern; Pernille Barkholt; Niels Vrang; Jacob Jelsing; Jacob Hecksher-Sørensen
Journal:  Neuroinformatics       Date:  2021-07

6.  A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats.

Authors:  Yafang Zhang; Suditi Rahematpura; Kael H Ragnini; Amanda Moreno; Kamryn S Stecyk; Michelle W Kahng; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt
Journal:  Neuropharmacology       Date:  2021-05-11       Impact factor: 5.273

7.  Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease.

Authors:  Urmas Roostalu; Casper B G Salinas; Ditte D Thorbek; Jacob L Skytte; Katrine Fabricius; Pernille Barkholt; Linu M John; Vanessa Isabell Jurtz; Lotte Bjerre Knudsen; Jacob Jelsing; Niels Vrang; Henrik H Hansen; Jacob Hecksher-Sørensen
Journal:  Dis Model Mech       Date:  2019-11-22       Impact factor: 5.758

8.  Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.

Authors:  Brandon T Milliken; Clinton Elfers; Oleg G Chepurny; Kylie S Chichura; Ian R Sweet; Tito Borner; Matthew R Hayes; Bart C De Jonghe; George G Holz; Christian L Roth; Robert P Doyle
Journal:  J Med Chem       Date:  2021-01-15       Impact factor: 7.446

9.  Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice.

Authors:  Henrik H Hansen; Rikke V Grønlund; Tamara Baader-Pagler; Peter Haebel; Harald Tammen; Leif Kongskov Larsen; Jacob Jelsing; Niels Vrang; Thomas Klein
Journal:  Sci Rep       Date:  2021-04-13       Impact factor: 4.379

10.  Investigation of Newly Diagnosed Drug-Naive Patients with Systemic Autoimmune Diseases Revealed the Cleaved Peptide Tyrosine Tyrosine (PYY 3-36) as a Specific Plasma Biomarker of Rheumatoid Arthritis.

Authors:  Jozsef A Balog; Agnes Kemeny; Laszlo G Puskas; Szilard Burcsar; Attila Balog; Gabor J Szebeni
Journal:  Mediators Inflamm       Date:  2021-06-17       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.